An emerging playbook for antibody-drug conjugates: Lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety

Current Opinion in Chemical Biology

Volumn 28, Issue , 2015, Pages 174-180

  Drake, Penelope M ^a   Rabuka, David ^a  

^a CATALENT PHARMA SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; BRENTUXIMAB VEDOTIN; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; DRUG;

CELL SURFACE; CLINICAL TRIAL (TOPIC); DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYDROPHOBICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG STABILITY; PROCEDURES;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG STABILITY; HUMANS; IMMUNOCONJUGATES; PHARMACEUTICAL PREPARATIONS;

EID: 84940838464     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2015.08.005     Document Type: Review

References (48)

1. Wang J., Watanabe J.H. AAPS Advances in the Pharmaceutical Sciences Series 2015, Springer International Publishing.
2. Bross P.F., Beitz J., Chen G., Chen X.H., Duffy E., Kieffer L., Roy S., Sridhara R., Rahman A., Williams G., et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001, 7:1490-1496.
3. Chari R.V.J., Miller M.L., Widdison W.C. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed 2014, 53:3796-3827.
4. Moore K., Martin L., Seward S., Bauer T., O'Malley D., Perez R., Oza A., Jeong W., Kirby M., Zhou Y., et al. Preliminary single agent activity of IMGN853, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial. Abstract 5518, ASCO, Annual Meeting 2015.
5. Sedlacek H.H. Antibodies As Carriers of Cytotoxicity 1992.
6. Erickson H.K., Lambert J.M. ADME of antibody-maytansinoid conjugates. AAPS J 2012, 14:799-805.
7. Bouchard H., Viskov C., Garcia-Echeverria C. Antibody-drug conjugates-a new wave of cancer drugs. Bioorg Med Chem Lett 2014, 24:5357-5363.
8. Liu Y., Zhang X., Han C., Wan G., Huang X., Ivan C., Jiang D., Rodriguez-Aguayo C., Lopez-Berestein G., Rao P.H., et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature 2015, 10.1038/nature14418.
9. Hong E.E., Chari R. AAPS Advances in the Pharmaceutical Sciences Series 2015, Springer International Publishing.
10. McCombs J.R., Owen S.C. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J 2015, 17:339-351.
11. Lyon R. Novel ADC Chemistry for Improved Stability and Pharmacokinetics 2014, PEGS Boston.
12. Hamblett K.J., Senter P.D., Chace D.F., Sun M.M.C., Lenox J., Cerveny C.G., Kissler K.M., Bernhardt S.X., Kopcha A.K., Zabinski R.F., et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004, 10:7063-7070.
13. Saber H., Leighton J.K. An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol 2015, 71:444-452.
14. Sukumaran S., Lin K. AAPS Advances in the Pharmaceutical Sciences Series 2015, Springer International Publishing.
15. Polson A.G., Calemine-Fenaux J., Chan P., Chang W., Christensen E., Clark S., de Sauvage F.J., Eaton D., Elkins K., Elliott J.M., et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009, 69:2358-2364.
16. Damelin M., Zhong W., Myers J., Sapra P. Evolving strategies for target selection for antibody-drug conjugates. Pharm Res 2015, 10.1007/s11095-015-1624-3.
17. Sadekar S., Figueroa I., Tabrizi M. Antibody drug conjugates: application of quantitative pharmacology in modality design and target selection. AAPS J 2015, 10.1208/s12248-015-9766-0.
18. Bander N.H. Antibody-drug conjugate target selection: critical factors. Methods Mol Biol 2013, 1045:29-40.
19. Tumey L.N., Charati M., He T., Sousa E., Ma D., Han X., Clark T., Casavant J., Loganzo F., Barletta F., et al. Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy. Bioconjug Chem 2014, 25:1871-1880.
20. Boswell C.A., Mundo E.E., Zhang C., Bumbaca D., Valle N.R., Kozak K.R., Fourie A., Chuh J., Koppada N., Saad O., et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 2011, 22:1994-2004.
21. Herbertson R.A., Tebbutt N.C., Lee F.-T., MacFarlane D.J., Chappell B., Micallef N., Lee S.-T., Saunder T., Hopkins W., Smyth F.E., et al. Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res 2009, 15:6709-6715.
22. Burke P.J., Hamilton J.Z., Jeffrey S.C., Hunter J.H., Doronina S.O., Okeley N.M., Anderson M.E., Senter P.D., Lyon R.P. Optimization of a PEGylated glucuronide-auristatin linker for antibody-drug conjugates. Abstract 648, AACR 2015.
23. Alley S.C., Benjamin D.R., Jeffrey S.C., Okeley N.M., Meyer D.L., Sanderson R.J., Senter P.D. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconj Chem 2008, 19:759-765.
24. Lyon R.P., Setter J.R., Bovee T.D., Doronina S.O., Hunter J.H., Anderson M.E., Balasubramanian C.L., Duniho S.M., Leiske C.I., Li F., et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat Biotechnol 2014, 32:1059-1062.
25. Drake P.M., Rabuka D. Antibody-drug conjugates: can coupling cytotoxicity and specificity overcome therapeutic resistance?. Resistance to Targeted Anti-Cancer Therapeutics 2013, 183-200. Springer.
26. Kovtun Y.V., Audette C.A., Mayo M.F., Jones G.E., Doherty H., Maloney E.K., Erickson H.K., Sun X., Wilhelm S., Ab O., et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010, 70:2528-2537.
27. Kellogg B.A., Garrett L., Kovtun Y., Lai K.C., Leece B., Miller M., Payne G., Steeves R., Whiteman K.R., Widdison W., et al. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 2011, 22:717-727.
28. Strop P., Liu S.-H., Dorywalska M., Delaria K., Dushin R.G., Tran T.-T., Ho W.-H., Farias S., Casas M.G., Abdiche Y., et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 2013, 20:161-167.
29. van der Lee M.M.C., Groothuis P.G., Ubink R., van der Vleuten M.A.J., van Achterberg T.A., Loosveld E.M., Damming D., Jacobs D.C.H., Rouwette M., Egging D.F., et al. The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Mol Cancer Ther 2015, 14:692-703.
30. Wang H., Rangan V.S., Sung M.-C., Passmore D., Kempe T., Wang X., Thevanayagam L., Pan C., Rao C., Srinivasan M., et al. Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans. Biopharm Drug Dispos 2015, 10.1002/bdd.1953.
31. Uppal H., Doudement E., Mahapatra K., Darbonne W.C., Bumbaca D., Shen B.Q., Du X., Saad O., Bowles K., Olsen S., et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res 2015, 21:123-133.
32. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012, 119:5640-5649.
33. Panowski S., Bhakta S., Raab H., Polakis P., Junutula J.R. Site-specific antibody drug conjugates for cancer therapy. mAbs 2013, 6:34-45.
34. Behrens C.R., Liu B. Methods for site-specific drug conjugation to antibodies. mAbs 2013, 6:46-53.
35. Jeffrey S.C., Burke P.J., Lyon R.P., Meyer D.W., Sussman D., Anderson M., Hunter J.H., Leiske C.I., Miyamoto J.B., Nicholas N.D., et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 2013, 24:1256-1263.
36. Kung Sutherland M.S., Walter R.B., Jeffrey S.C., Burke P.J., Yu C., Kostner H., Stone I., Ryan M.C., Sussman D., Lyon R.P., et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013, 122:1455-1463.
37. Liu S.-H., Strop P., Tran T.-T., Dorywalsk M., Delaria K., Ho W.-H., Dushin R., Pons J., Rajpal A., Shelton D. RN927C, a potent site-specific Trop-2 antibody-drug-conjugate (ADC) for treatment of solid tumors. Cancer Res 2014, 74. Abstract 2640; AACR Annual Meeting, April 2014, San Diego, CA.
38. Junutula J.R., Raab H., Clark S., Bhakta S., Leipold D.D., Weir S., Chen Y., Simpson M., Tsai S.P., Dennis M.S., et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008, 26:925-932.
39. Zimmerman E.S., Heibeck T.H., Gill A., Li X., Murray C.J., Madlansacay M.R., Tran C., Uter N.T., Yin G., Rivers P.J., et al. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug Chem 2014, 25:351-361.
40. Axup J.Y., Bajjuri K.M., Ritland M., Hutchins B.M., Kim C.H., Kazane S.A., Halder R., Forsyth J.S., Santidrian A.F., Stafin K., et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci 2012, 109:16101-16106.
41. Drake P.M., Albers A.E., Baker J., Banas S., Barfield R.M., Bhat A.S., de Hart G.W., Garofalo A.W., Holder P., Jones L.C., et al. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug Chem 2014, 25:1331-1341.
42. Albers A.E., Garofalo A.W., Drake P.M., Kudirka R., de Hart G.W., Barfield R.M., Baker J., Banas S., Rabuka D. Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates. Eur J Med Chem 2014, 88:3-9.
43. Jackson D., Atkinson J., Guevara C.I., Zhang C., Kery V., Moon S.-J., Virata C., Yang P., Lowe C., Pinkstaff J., et al. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. PLoS ONE 2014, 9:e83865.
44. Junutula J.R., Flagella K.M., Graham R.A., Parsons K.L., Ha E., Raab H., Bhakta S., Nguyen T., Dugger D.L., Li G., et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 2010, 16:4769-4778.
45. Shen B.-Q., Xu K., Liu L., Raab H., Bhakta S., Kenrick M., Parsons-Reponte K.L., Tien J., Yu S.-F., Mai E., et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012, 30:184-189.
46. Rabuka D. Distinct in vivo efficacy and PK outcomes of ADCs conjugated site specifically using SMARTag™ technology 2015.
47. Boswell C.A., Mundo E.E., Zhang C., Stainton S.L., Yu S.F., Lacap J.A., Mao W., Kozak K.R., Fourie A., Polakis P., et al. Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med 2012, 53:1454-1461.
48. Sagert J., West J., Wong C., Desnoyers L., Vasiljeva O., Richardson J., Polu K., Lowman H. Transforming Notch ligands into tumor-antigen targets: a probody-drug conjugate (PDC) targeting Jagged 1 and Jagged 2. 2014.